pacc1 Antibody

What is PACC1 and what is its biological significance?

PACC1 (also designated TMEM206) is the molecular entity underlying proton-activated chloride channels. It functions as a transmembrane protein that forms chloride channels activated by extracellular acidic pH. Structurally, PACC1 possesses two transmembrane domains with cytoplasmic N- and C-termini and a large extracellular loop, resembling the architecture of sodium-selective channels like ASICs and ENaCs. Current evidence suggests that the functional unit of the proton-activated chloride channel exists as a trimeric assembly of PACC1 subunits . These channels have been characterized electrophysiologically in various cell types and tissues before their molecular identity was established. The biological significance of PACC1 extends to multiple contexts including acidosis-related pathological conditions such as cerebral and cardiac ischemia, cancer progression, and inflammatory processes. Recent research has also implicated PACC1 in endosomal pathways and acid-induced cell death mechanisms .

How can I determine which epitope of PACC1 is optimal for antibody targeting in my experimental system?

Selecting the optimal epitope for PACC1 antibody targeting requires careful consideration of both the protein's topology and your experimental objectives. For surface detection applications (flow cytometry, live cell imaging), extracellular epitopes are preferable as demonstrated by successful detection of PACC1 in intact THP-1 cells using antibodies targeting the extracellular loop epitope corresponding to amino acid residues 95-110 . This region in mouse PACC1 ((C)KLKHPVMSVSYKEVDR sequence) has proven effective for generating antibodies that recognize PACC1 across multiple species (mouse, rat, human) .

For intracellular applications, cytoplasmic N- or C-terminal epitopes may be more appropriate, though this requires cell permeabilization. When designing experiments, consider that extracellular domain antibodies may potentially interfere with channel function, which could be either advantageous (for functional studies) or problematic (for expression studies without functional perturbation). Additionally, evaluate sequence conservation of your target epitope across species if cross-reactivity is desired. Confirming accessibility of the epitope in your experimental conditions through pilot studies using different fixation protocols is recommended before proceeding to larger-scale investigations.

What validation methods should I use to confirm PACC1 antibody specificity?

Comprehensive validation of PACC1 antibody specificity requires multiple complementary approaches:

• Blocking peptide controls: Pre-incubation of the primary PACC1 antibody with the immunizing peptide should abolish or substantially reduce signal in western blot, immunohistochemistry, and flow cytometry applications. This approach has been successfully employed with the PACC1/TMEM206 extracellular blocking peptide to demonstrate specificity in various tissues including mouse brain sections .

• Genetic controls: Tissues or cells from PACC1 knockout models (Pacc1-/-) provide the gold standard negative control. Compare antibody reactivity in wild-type versus knockout samples across multiple applications to confirm specificity .

• Multiple antibody validation: When available, use antibodies targeting different epitopes of PACC1 and confirm consistent localization patterns.

• Signal correlation with expression levels: Verify that antibody signal intensity correlates with known or experimentally manipulated expression levels. For example, temporal expression analysis during RANKL-induced osteoclast differentiation showed that both PACC1 mRNA and protein levels peaked at day 3, providing concordant evidence for antibody specificity .

• Expected molecular weight verification: Confirm that the detected band in western blot corresponds to the predicted molecular weight of PACC1 (~40 kDa, though post-translational modifications may alter migration).

Document all validation steps methodically, as antibody specificity challenges represent a significant source of irreproducibility in biomedical research.

What are the optimal protocols for detecting PACC1 expression in different tissue types and cellular contexts?

Optimal protocols for PACC1 detection vary by tissue type and experimental objective:

For Neural Tissues:
Immunohistochemical detection of PACC1 in neural tissues has been successfully performed using perfusion-fixed frozen mouse brain sections. The protocol involves incubation with anti-PACC1/TMEM206 extracellular antibody (1:200 dilution), followed by secondary detection with goat anti-rabbit-AlexaFluor-488 . This approach revealed PACC1 immunoreactivity in neurons of the mouse reticular thalamic nucleus. Neural tissue typically requires careful fixation and antigen retrieval optimization to balance structural preservation with epitope accessibility.

For Bone and Cartilage:
Detection of PACC1 in bone tissues presents unique challenges due to decalcification requirements. Successful co-immunostaining of PACC1 with TRAP (tartrate-resistant acid phosphatase) on human bone sections has demonstrated that PACC1 localizes to the cellular membrane and intracellular organelles of osteoclasts at the bone surface . When working with spine endplate tissues, consider complementing immunostaining with other techniques like SOFG (Safranin O and fast green) staining to visualize cartilage area and endplate porosity changes in relation to PACC1 expression .

For Cell Lines:
Western blot analysis has been effective for PACC1 detection in diverse cell lines including human U-87 MG glioblastoma, HT-29 colon adenocarcinoma, THP-1 monocytic leukemia, and mouse BV-2 microglia using 1:200 antibody dilution . For flow cytometry applications with live intact cells, successful detection has been demonstrated in THP-1 cells using 2.5μg of anti-PACC1/TMEM206 extracellular antibody followed by goat-anti-rabbit-FITC secondary detection .

For all applications, include appropriate positive and negative controls, and consider the impact of pH conditions on PACC1 expression and localization, given its function as a proton-activated channel.

How can I optimize western blot protocols for PACC1 detection in different sample types?

Optimizing western blot protocols for PACC1 detection requires attention to several critical parameters:

Sample Preparation:

• For membrane proteins like PACC1, membrane fractionation may improve detection sensitivity. This approach has been successfully used for mouse brain membranes .

• Include protease inhibitors in lysis buffers to prevent degradation.

• For tissues with high protease activity (like brain), rapid sample processing at cold temperatures is essential.

Protein Loading and Transfer:

• Adjust protein loading based on expected PACC1 expression levels (typically 20-50μg total protein).

• For transmembrane proteins like PACC1, optimize transfer conditions: consider using lower methanol concentrations in transfer buffer and longer transfer times.

Antibody Conditions:

• Anti-PACC1/TMEM206 extracellular antibody has been successfully used at 1:200 dilution for various sample types including rat brain lysate, mouse brain membranes, rat kidney lysates, and multiple cell lines .

• Include validation controls in each experiment: pre-adsorption with blocking peptide has been shown to effectively eliminate signal, confirming specificity .

Detection Optimization:

• If signal is weak, consider signal amplification methods or more sensitive ECL substrates.

• For quantitative analysis, verify linear range of detection and normalize to appropriate loading controls.

A systematic evaluation of these parameters through pilot experiments will help establish optimal conditions for your specific sample types and research questions.

What approaches can I use to study PACC1 function alongside expression patterns?

Integrating functional analysis with expression studies of PACC1 requires multifaceted experimental approaches:

Electrophysiological Methods:
Whole-cell patch clamping has been effectively employed to measure proton-activated currents in PACC1-expressing cells. This technique confirmed that extracellular acidosis evokes PAC currents in wild-type preosteoclasts at day 3 after RANKL treatment, while these currents were absent in Pacc1 knockout cells . When designing electrophysiological experiments, consider examining current-voltage relationships under varying pH conditions to characterize channel properties.

Genetic Manipulation Approaches:

• Knockout models: Pacc1-/- mice have provided valuable insights into PACC1 function in vivo, revealing its role in osteoclast fusion and endplate porosity in spine degeneration models without affecting normal bone development .

• RNA interference: For acute depletion studies, siRNA or shRNA approaches can be combined with antibody detection to correlate knockdown efficiency with functional outcomes.

Functional Readouts:

• For osteoclast studies, combine PACC1 expression analysis with functional assays such as TRAP staining to quantify multinuclear osteoclast formation .

• In neurological contexts, sensory nerve innervation (e.g., CGRP immunostaining) can serve as a functional correlate to PACC1 expression and manipulation .

Pharmacological Approaches:
While specific pharmacological tools for PACC1 are still being developed, chloride channel blockers can be used in conjunction with genetic approaches to dissect PACC1-specific effects from other chloride conductances.

This multidimensional approach allows researchers to correlate PACC1 expression patterns with functional consequences in physiological and pathological contexts.

How can protein language models enhance PACC1 antibody selection and optimization for research applications?

Protein language models represent a cutting-edge approach that can significantly enhance PACC1 antibody selection and optimization through computational prediction of developability characteristics:

The AntiBERTy language model encoding system has demonstrated remarkable capability in discriminating between antibodies likely to succeed in clinical development versus those likely to be discontinued. This approach exploits subtle sequence features that traditional physicochemical property analyses may miss . For PACC1 antibody research, this methodology could be adapted to:

• Pre-screen candidate antibodies: By encoding candidate anti-PACC1 antibody sequences and comparing them against the distribution patterns of successful antibodies in the encoded parameter space, researchers can identify those with optimal developability profiles before committing resources to expression and purification.

• Optimize complementarity-determining regions (CDRs): The language model approach can guide rational design of CDR modifications that maintain target specificity while improving developability characteristics such as stability and reduced immunogenicity risk.

• Develop triaging pipelines: A multi-layered selection approach combining physicochemical filtering with unsupervised clustering of encoded antibodies (Layer 1) followed by supervised classification (Layer 2) can efficiently identify promising anti-PACC1 antibody candidates from diverse libraries .

This pipeline approach demonstrated by recent research achieved surprisingly good performance using basic predictive models that could distinguish between approved and discontinued antibodies, despite no statistically significant differences in conventional features like isoelectric point, thermostability, or CDR-H3 length . For PACC1 research applications, implementing such computational prescreening could significantly reduce the time and resources required to develop high-quality antibody reagents, particularly for challenging applications requiring high specificity and minimal cross-reactivity.

What specialized techniques can I use to investigate PACC1 localization and trafficking in live cells?

Investigating PACC1 localization and trafficking in live cells requires specialized approaches that preserve physiological dynamics:

Live-Cell Surface Labeling Techniques:
Antibodies targeting the extracellular domain of PACC1, such as those recognizing amino acid residues 95-110 of the extracellular loop, are particularly valuable for live-cell applications. Flow cytometry with intact live THP-1 cells has successfully demonstrated cell surface detection of PACC1 using anti-PACC1/TMEM206 extracellular antibody (2.5μg) followed by fluorophore-conjugated secondary antibody . This approach can be adapted for time-lapse microscopy to track dynamic changes in surface expression.

pH-Sensitive Fluorescent Probes:
Given PACC1's sensitivity to extracellular pH, combining antibody labeling with pH-sensitive fluorophores can provide functional correlation with localization. Consider using ratiometric pH indicators alongside fluorescently-tagged anti-PACC1 antibodies to simultaneously track localization and local pH changes.

Antibody Fragment Approaches:
For applications where full IgG antibodies may cause steric hindrance or alter trafficking, consider developing Fab or scFv fragments from validated anti-PACC1 antibodies. These smaller formats may provide improved access to restricted cellular compartments while maintaining specificity.

Pulse-Chase Labeling Strategies:
To track PACC1 internalization and recycling dynamics, employ pulse-chase approaches using differently labeled antibodies at sequential time points. This can distinguish newly synthesized from recycled PACC1 channels at the cell surface.

Co-localization with Endosomal Markers:
Given PACC1's involvement in endocytic pathways, simultaneous labeling with markers for early endosomes (EEA1), late endosomes (Rab7), recycling endosomes (Rab11), or lysosomes (LAMP1) can provide mechanistic insights into PACC1 trafficking in response to various stimuli, particularly pH changes.

These approaches can be particularly valuable when investigating PACC1 dynamics in the context of acid-induced pathways relevant to cancer, inflammation, and ischemic conditions.

How can I interpret contradictory findings when using different PACC1 antibodies in my research?

Interpreting contradictory findings when using different PACC1 antibodies requires systematic troubleshooting and careful experimental design:

Epitope-Specific Effects:
Different antibodies targeting distinct epitopes of PACC1 may yield varied results due to:

• Epitope accessibility: Certain epitopes may be masked under specific experimental conditions or in particular cellular contexts.

• Post-translational modifications: Some antibodies may recognize epitopes subject to phosphorylation, glycosylation, or other modifications that vary across cell types or conditions.

• Protein conformational states: PACC1 may adopt different conformational states when activated by protons, potentially affecting epitope recognition.

Resolution Strategies:

• Comprehensive validation: Validate each antibody using multiple approaches including blocking peptide controls, genetic controls (Pacc1-/- samples), and correlation with mRNA expression .

• Epitope mapping: Determine the precise epitopes recognized by each antibody and evaluate whether structural features of PACC1 might differentially affect their accessibility.

• Cross-validation with non-antibody methods: Complement antibody-based detection with orthogonal techniques such as mRNA quantification through RT-PCR, which has shown concordant results with protein detection during osteoclast differentiation studies .

• Controlled pH conditions: Given PACC1's sensitivity to pH, ensure that pH conditions are carefully controlled and consistent across experiments, as variations could affect channel conformation and antibody binding.

• Application-specific validation: An antibody performing well in western blot may not be optimal for immunohistochemistry or flow cytometry. Testing each antibody specifically for your application is essential.

When presenting results from multiple antibodies with discrepant findings, transparently report all validation steps performed and consider biological explanations for the differences observed, such as cell-type specific post-translational modifications or protein interactions that might mask particular epitopes.

How can PACC1 antibodies be used to investigate its role in disease models?

PACC1 antibodies serve as essential tools for investigating disease mechanisms across multiple models:

In Spine Degeneration and Low Back Pain Models:
Immunohistochemical applications of PACC1 antibodies have been instrumental in elucidating the role of this channel in spine degeneration-associated low back pain. Research using lumbar spine instability (LSI) mouse models revealed that genetic deletion of Pacc1 reduced endplate porosity and attenuated pain behaviors . Combined with TRAP staining to identify osteoclasts, PACC1 antibodies helped establish the mechanistic link between channel activity, osteoclast function, and pain development. This approach demonstrated that PACC1 antibodies can effectively track expression changes in complex tissue microenvironments relevant to degenerative diseases.

In Cancer Research Applications:
Given that upregulation of PACC1 is associated with poor prognosis in hepatocellular carcinoma , PACC1 antibodies can be employed to:

• Assess expression patterns in patient-derived xenograft models

• Monitor changes in PACC1 localization in response to acidic tumor microenvironments

• Correlate expression with invasion and metastatic potential in various cancer cell lines

In Cerebral Ischemia Models:
PACC1's implication in acid-induced cell death and brain damage after ischemic stroke suggests valuable applications for antibodies in stroke models:

• Temporal and spatial mapping of PACC1 expression changes following ischemic insults

• Correlation of channel expression with neuronal damage markers

• Evaluation of potential therapeutic interventions targeting PACC1

Methodological Considerations:
When designing experiments with disease models, researchers should consider:

• Timing of sample collection relative to disease progression

• Selection of appropriate controls (both negative controls using blocking peptides and positive controls from tissues known to express PACC1)

• Combination with functional readouts specific to the disease context (e.g., behavioral assessments in pain models)

• Correlation with human patient samples when available to establish translational relevance

These approaches demonstrate how PACC1 antibodies can bridge mechanistic understanding with potential therapeutic applications across multiple disease contexts.

What strategies can mitigate potential interference of PACC1 antibodies with channel function in functional studies?

Mitigating antibody interference with PACC1 channel function requires strategic experimental design:

Epitope Selection Considerations:
When studying channel function, carefully consider antibody binding sites. Antibodies targeting the extracellular domain (like those recognizing amino acids 95-110 in the extracellular loop) may potentially interfere with proton sensing or channel gating. For functional studies where channel activity must remain unperturbed, consider:

• Intracellular epitope targeting: Antibodies recognizing cytoplasmic N- or C-terminal epitopes are less likely to interfere with channel function but require cell permeabilization for live imaging applications.

• Non-functional epitope confirmation: Through structure-function analysis, identify epitopes distant from the proton-sensing or pore-forming regions of PACC1. Antibodies targeting these regions may be less likely to alter channel function.

Experimental Design Strategies:

Validation Approaches:
To confirm whether an antibody affects channel function:

• Compare electrophysiological properties of PACC1 channels before and after antibody application

• Assess dose-dependent effects of antibody on channel activity

• Compare effects of F(ab) fragments (which lack Fc regions) with full IgG antibodies to distinguish between steric hindrance and Fc-mediated effects

These strategies enable researchers to navigate the potential tradeoffs between detection sensitivity and functional interference when studying PACC1 channels in various experimental contexts.

How can I quantitatively assess PACC1 expression changes in response to therapeutic interventions?

Quantitative assessment of PACC1 expression changes following therapeutic interventions requires rigorous methodological approaches:

Western Blot Quantification:
For protein-level quantification, western blot analysis has been successfully applied to various tissues including brain, kidney, and multiple cell lines . To ensure accurate quantification:

• Establish standard curves with recombinant PACC1 protein to confirm linear detection range

• Normalize to appropriate loading controls that remain stable under your experimental conditions

• Include internal reference samples across multiple blots to allow inter-blot comparisons

• Use digital image analysis with background subtraction for densitometric quantification

• Apply statistical analysis to determine significance of observed changes

RT-PCR for Transcriptional Assessment:
RT-PCR has effectively demonstrated temporal changes in Pacc1 mRNA expression, as seen during RANKL-stimulated osteoclast differentiation . This approach complements protein-level analysis and can reveal transcriptional regulation mechanisms. Consider:

• Designing primers specific to relevant Pacc1 transcript variants

• Using multiple reference genes validated for stability under your experimental conditions

• Employing quantitative PCR (qPCR) with standard curves to determine absolute transcript numbers

Flow Cytometric Analysis:
For cell surface expression quantification, flow cytometry with anti-PACC1 extracellular antibodies enables:

• Single-cell resolution assessment of expression changes

• Quantification using calibrated fluorescence standards

• Multiparametric analysis correlating PACC1 expression with cell type markers or functional readouts

Immunohistochemical Quantification:
For tissue sections, quantitative immunohistochemistry can assess:

• Changes in expression intensity (mean fluorescence intensity)

• Alterations in subcellular localization patterns

• Cell-type specific expression changes in complex tissues

Experimental Design Considerations:

This multi-tiered approach allows comprehensive assessment of PACC1 expression changes across different biological levels and time scales, providing mechanistic insights into therapeutic intervention effects.

How might single-cell analysis techniques advance our understanding of PACC1 heterogeneity in complex tissues?

Single-cell analysis techniques offer unprecedented opportunities to unravel PACC1 heterogeneity across diverse cell populations within complex tissues:

Single-Cell Antibody-Based Approaches:
Flow cytometry using anti-PACC1 extracellular antibodies has already demonstrated effectiveness for detecting surface expression in intact cells . This foundation can be expanded through:

• Mass cytometry (CyTOF): By conjugating PACC1 antibodies to metal isotopes rather than fluorophores, researchers can overcome spectral overlap limitations and simultaneously assess PACC1 expression alongside dozens of other markers, enabling comprehensive phenotyping of PACC1-expressing cells in heterogeneous tissues.

• Imaging mass cytometry: This technique combines the multiplex capabilities of mass cytometry with spatial resolution, allowing visualization of PACC1 expression patterns within tissue architecture while preserving information about cellular neighborhoods and microenvironmental factors.

• Single-cell Western blotting: For situations where antibody specificity in flow cytometry is challenging, this emerging technique separates proteins from individual cells by size before antibody detection, potentially improving specificity.

Integration with Transcriptomic Approaches:
Complementing antibody-based protein detection with transcriptomic analysis can reveal regulatory mechanisms governing PACC1 expression:

• CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing): This approach combines surface protein detection (using antibodies conjugated to oligonucleotide barcodes) with single-cell RNA sequencing, allowing correlation between PACC1 surface expression and transcriptional profiles at single-cell resolution.

• Spatial transcriptomics: These techniques maintain spatial information while capturing transcriptional data, enabling mapping of PACC1 mRNA expression patterns within tissue contexts like the complex cellular architecture of endplates in spine degeneration models .

Anticipated Research Insights:
These approaches could address critical questions including:

• Which specific osteoclast subtypes express PACC1 during spine degeneration progression?

• How does PACC1 expression correlate with proton-sensing machinery in different neuronal populations?

• What transcriptional programs accompany PACC1 upregulation in cancer contexts?

• How heterogeneous is PACC1 expression within apparently uniform cell populations?

These single-cell approaches are poised to transform our understanding of PACC1 biology by revealing cell-type specific regulatory mechanisms and functional consequences that may be obscured in bulk tissue analyses.

What are the considerations for developing function-blocking antibodies against PACC1 for research and potential therapeutic applications?

Developing function-blocking antibodies against PACC1 involves several key considerations spanning epitope selection, validation strategies, and application-specific optimizations:

Strategic Epitope Targeting:
Effective function-blocking antibodies must target domains critical for channel activity. For PACC1:

• Proton-sensing domains: Antibodies directed against regions involved in pH sensing could prevent channel activation by extracellular acidosis.

• Pore-forming regions: Targeting residues that form the chloride-conducting pore might directly block ion flow.

• Extracellular loop epitopes: The large extracellular loop of PACC1 (including residues 95-110 in mouse PACC1) represents an accessible target for function-blocking antibodies. This region may contribute to channel gating or subunit assembly into functional trimers .

Functional Validation Approaches:

Format Optimization:
Different antibody formats offer distinct advantages for function-blocking applications:

• Full IgG: Provides extended half-life and potential for Fc-mediated effects

• F(ab')2 fragments: Eliminates Fc-mediated effects while maintaining bivalent binding

• Fab fragments: Offers smaller size for improved tissue penetration

• Single-domain antibodies: May access restricted epitopes due to minimal size

Translation Considerations:
For potential therapeutic development beyond research applications:

• Species cross-reactivity: Antibodies recognizing conserved epitopes across human, mouse, and rat PACC1 facilitate translation from preclinical models to human applications.

• Developability assessment: Applying computational approaches like those used in antibody developability triaging pipelines can help select candidates with favorable biophysical properties and reduced immunogenicity risk.

• Tissue-specific targeting: For conditions like spine degeneration-associated low back pain , strategies for delivering function-blocking antibodies specifically to affected tissues could minimize off-target effects.

These considerations provide a framework for developing function-blocking PACC1 antibodies that could serve both as valuable research tools and as starting points for potential therapeutic development in conditions where PACC1 inhibition shows promise, such as spine degeneration-associated low back pain .

How might advancements in structural biology techniques enhance PACC1 antibody design and application specificity?

Structural biology advancements are poised to revolutionize PACC1 antibody design through detailed molecular insights:

Cryo-Electron Microscopy (Cryo-EM) Applications:
Recent advancements in cryo-EM have enabled high-resolution structural determination of membrane proteins like ion channels. For PACC1, which forms trimeric assemblies , cryo-EM could reveal:

• Conformational states: Structures of PACC1 in both closed and proton-activated open states would identify dynamic regions that undergo conformational changes during gating.

• Antibody-epitope complexes: Visualizing antibody-PACC1 complexes could precisely map binding interfaces, revealing whether antibodies stabilize particular channel conformations.

• Species-specific structural variations: Comparing human, mouse, and rat PACC1 structures could identify conserved regions optimal for developing cross-species reactive antibodies .

X-ray Crystallography Contributions:
While challenging for full-length membrane proteins, crystallography may prove valuable for:

• Soluble domain structures: Crystallizing the large extracellular loop of PACC1 (containing amino acids 95-110 targeted by existing antibodies) could provide atomic-resolution details of antibody interaction sites.

• Antibody-epitope complexes: Co-crystallization of antibody fragments with PACC1 peptides would reveal precise molecular recognition determinants.

Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):
This technique, which measures solvent accessibility of protein regions, could:

• Identify pH-sensitive conformational changes in PACC1

• Map regions protected by antibody binding

• Reveal allosteric effects of antibody binding on distant channel regions

Computational Structure-Based Design:
Integrating experimental structural data with computational approaches enables:

• Epitope optimization: In silico design of antibodies with enhanced specificity for particular PACC1 conformations or states

• Cross-reactivity prediction: Computational assessment of epitope conservation across species

• Function prediction: Molecular dynamics simulations to predict how antibody binding affects channel dynamics

Anticipated Research Impact:
These structural insights would significantly advance PACC1 antibody applications by:

• Enabling design of conformation-specific antibodies that distinguish between inactive and proton-activated PACC1 states

• Facilitating development of antibodies that selectively recognize PACC1 in specific cellular contexts (e.g., acidified endosomes versus plasma membrane)

• Supporting structure-guided engineering of antibodies with improved specificity, affinity, and reduced cross-reactivity with related channels

• Providing structural foundations for developing small molecule modulators alongside antibody-based approaches

As structural biology techniques continue to advance, their integration with antibody engineering platforms and functional validation approaches will accelerate the development of next-generation PACC1 research tools with unprecedented specificity and utility.